Nanoscope Therapeutics Welcomes Troy Short as VP for Manufacturing Operations

Nanoscope Therapeutics Welcomes Troy Short as Senior Vice President of Manufacturing and Supply Chain

Nanoscope Therapeutics, a pioneer in biotechnology focused on advancing therapies for vision impairment, has made a significant leadership appointment with the recruitment of Troy Short as Senior Vice President of Manufacturing and Supply Chain. This strategic move comes as Nanoscope is gearing up for the potential approval of its groundbreaking therapy MOGENRY (sonpiretigene isteparvovec), intended for patients suffering from inherited retinal dystrophies (IRDs).

Troy Short: A Wealth of Experience in Gene Therapy

With over 20 years in operations and supply chain management, Troy Short is stepping into a role that places him at the forefront of Nanoscope’s push towards regulatory approval and eventual market launch for MOGENRY. His previous experiences include leadership roles at AveXis, Inc., where he was instrumental in launching Zolgensma®, a pioneering AAV gene therapy, across over 30 countries. Short's expertise spans various aspects of supply chain management, such as GMP manufacturing, global clinical supply, and the critical execution of therapeutic launches.

Short has a track record of achievements, having managed intricate supply chain logistics, negotiated key supplier agreements, and ensured the successful design and implementation of systems mandatory for regulatory compliance and operational readiness. His insights into the gene therapy space will significantly enhance Nanoscope's capabilities to deliver MOGENRY efficiently and effectively to patients in need.

Preparing for Global Commercialization

In his new role at Nanoscope, Short's primary responsibilities will involve overseeing the manufacturing processes, commercial supply strategies, and global distribution systems. This is crucial as the company nears the final stages of obtaining approval, with the FDA currently reviewing the Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa. Furthermore, Nanoscope is also seeking approval in Japan, where a New Drug Application (JNDA) is under review by the PMDA.

CEO Sulagna Bhattacharya stated, “Having someone like Troy who has successfully built and managed a supply chain that delivered an approved AAV gene therapy is invaluable to us. It reflects our commitment to quality and the serious preparations we are undertaking for the launch of MOGENRY.” The potential rollout of MOGENRY is particularly noteworthy as it offers a one-time treatment option that doesn't require genetic testing, ensuring seamless integration into existing clinical workflows.

MOGENRY: The Future of Gene Therapy

MOGENRY represents a leap forward in therapeutic strategies for inherited retinal diseases. Utilizing Nanoscope’s proprietary multi-characteristic opsin (MCO) technology, it aims to restore vision by converting surviving retinal cells into light-sensitive entities, circumventing the shortcomings of conventional gene therapies that often target single genetic mutations.

The company carries an ambitious vision not only to alleviate the suffering caused by IRDs but also to lead in the global commercialization of such transformative therapies. Short’s appointment delineates Nanoscope's pathway to not only boost operational efficiency but also ensure that when MOGENRY gains FDA acceptance, it will be readily available to patients without delay.

Conclusion

As Nanoscope Therapeutics continues to expand its clinical and commercial landscape with MOGENRY, Troy Short’s leadership is expected to facilitate strategic advancements in the company’s manufacturing efficacy and supply chain robustness. His initiation into the company marks an essential step in the pervasive goal to bring hope and healing to millions affected by retinal degeneration worldwide. As the company prepares for the launch, industry watchers remain optimistic about the prospect of MOGENRY setting a new standard for treatment—one that is set to revolutionize care for patients plagued by vision loss.

Learn more about Nanoscope’s initiatives and cutting-edge therapies at NanoscopeTherapeutics.com and stay connected with their latest updates on LinkedIn and Twitter.